P58.42 Neonatal jaundice due to drugs or toxins given to newborn

Name of the Condition

• Neonatal jaundice due to drugs or toxins given to newborn
• ICD-10-CM Code: P58.42

Summary

This condition describes jaundice in a newborn resulting from increased bilirubin levels caused by exposure to drugs or toxins administered to the infant. It occurs when substances disrupt normal bilirubin metabolism or accelerate red blood cell breakdown, leading to visible yellowing of the skin and eyes.

Causes

Drugs or toxins given to the newborn can interfere with bilirubin processing or cause hemolysis, increasing bilirubin production. Examples include certain medications (e.g., sulfonamides, vitamin K analogs) or substances that impair liver function or red blood cell stability. These agents overwhelm the newborn's immature liver, resulting in jaundice.

Risk Factors

• Administration of medications known to affect bilirubin metabolism (e.g., sulfonamides, vitamin K3)
• Exposure to toxins or substances with hemolytic properties
• Prematurity (reduced liver capacity to process bilirubin)
• Concurrent conditions affecting liver function or red blood cell turnover

Symptoms

• Yellowing of the skin and eyes (jaundice)
• Dark urine or pale stools
• Lethargy or poor feeding
• Irritability or high-pitched crying
• In severe cases, signs of bilirubin encephalopathy (e.g., arching, seizures)

Diagnosis

Diagnosis involves assessing bilirubin levels (total and direct) and evaluating for hemolysis. A detailed medication or toxin exposure history is critical. Laboratory tests may include blood counts, liver function tests, and toxicology screening if exposure is suspected. Imaging or other studies may be used to rule out other causes of jaundice.

Treatment Options

Treatment focuses on addressing the underlying cause, discontinuing the offending agent, and managing bilirubin levels. Phototherapy is commonly used to reduce bilirubin. In severe cases, exchange transfusion may be necessary. Supportive care, such as hydration and feeding support, is also provided.

Prognosis and Follow-Up

Prognosis depends on the severity of bilirubin elevation and timely intervention. Most cases resolve with treatment, but delayed care can lead to complications. Follow-up includes monitoring bilirubin levels and assessing for long-term effects, especially if encephalopathy occurred.

Complications

• Bilirubin encephalopathy (kernicterus) with potential neurological damage
• Hearing loss or developmental delays (if severe jaundice persists)
• Liver dysfunction if the underlying cause affects hepatic function

Lifestyle & Prevention

Prevention involves careful medication selection and dosing in newborns, avoiding known hepatotoxic or hemolytic agents. Healthcare providers should review drug safety profiles before administration. Monitoring for early jaundice signs is recommended in at-risk infants.

When to Seek Professional Help

Seek immediate medical attention if jaundice appears within the first 24 hours, worsens rapidly, or is accompanied by lethargy, poor feeding, or signs of encephalopathy. Prompt evaluation is critical to prevent complications.

Tips for Medical Coders

Document the specific drug or toxin exposure and its relationship to the jaundice. Include details on administration timing, dosage, and clinical correlation. Ensure the code P58.42 is used only when the jaundice is directly attributed to substances given to the newborn, with clear documentation supporting the causal link.